WAY-316606

WAY-316606 is a small-molecule antagonist of secreted frizzled-related protein 1 (SFRP1), an extracellular Wnt decoy that throttles canonical Wnt/β-catenin signalling in the dermal papilla. By tying up SFRP1, the compound frees endogenous Wnt ligands to engage the LRP5/6–Frizzled complex, stabilise β-catenin, and drive the TCF/LEF transcription that keeps hair follicles in anagen. Unlike finasteride, the mechanism is entirely non-hormonal — it has no effect on DHT, the androgen receptor, or the HPTA — which is the entire reason it appears in looksmaxxing and on-cycle hair stacks.

SFRP1 Antagonism and the Wnt Brake#

SFRP1 is a soluble decoy receptor that binds Wnt ligands before they can reach Frizzled, effectively acting as a brake on the pathway. WAY-316606 binds SFRP1 with sub-micromolar potency and displaces this interaction, allowing endogenous Wnt signalling to proceed at the level the follicle is "trying" to run at. The original medicinal-chemistry work characterised this in a Wnt reporter assay:

"Compound 1 (WAY-316606) increased Wnt signaling with an EC50 of approximately 0.65 μM in WNT3-expressing U2OS cells, demonstrating potent SFRP1 antagonism." — Moore WJ et al., J Med Chem, 2009

Critically, the mechanism is ligand-limited — WAY-316606 cannot force Wnt signalling where no ligand is being expressed. That is the basis of the argument that it should be safer than direct β-catenin stabilisers or GSK-3 inhibitors, which can drive the pathway in tissues that were not asking for it.

Anagen Prolongation in the Hair Follicle#

The dermal papilla expresses high SFRP1 throughout the hair cycle, which is exactly why follicles susceptible to androgenetic miniaturisation lose anagen length so readily — the Wnt brake is on hard. Hawkshaw's group at Manchester mapped this onto cyclosporine A's well-known hypertrichotic side effect and showed that CsA's pro-growth signal is mediated through SFRP1 suppression, then demonstrated that hitting the same node directly with WAY-316606 reproduces the effect:

"WAY-316606, a specific SFRP1 antagonist, significantly enhanced human hair shaft elongation and hair keratin expression in cultured human scalp hair follicles." — Hawkshaw NJ et al., PLoS Biol, 2018

In that ex vivo human scalp model, 5 µM WAY-316606 enhanced shaft elongation within two days, upregulated hair keratin K85, prolonged anagen, and suppressed spontaneous catagen entry. Translated to the practical outcome: longer growth phase, thicker shafts, and delayed shedding — the same axis minoxidil targets, but through a different upstream node.

Independence from the Androgen Axis#

This is where the compound earns its place in the on-cycle toolkit. WAY-316606 does not bind the androgen receptor, does not inhibit 5α-reductase, does not aromatise, and has no documented effect on LH, FSH, total testosterone, free testosterone, or DHT. It addresses the Wnt arm of follicle biology, not the androgenic arm. For users running heavy AAS who refuse oral finasteride or dutasteride because of post-finasteride sexual side-effect concerns, that pathway separation is the entire point — pair WAY-316606 with a topical AR antagonist (RU58841, pyrilutamide, clascoterone) and both choke points are covered without any systemic 5-AR exposure.

Downstream Wnt Effects Beyond the Follicle#

The same mechanism has been characterised in other Wnt-dependent tissues, which is useful context for understanding what chronic topical exposure is doing biologically (and why systemic dosing is not on the table for hair use).

"Oral administration of WAY-316606 to ovariectomized mice significantly increased bone formation and restored bone mass by enhancing endogenous Wnt signaling." — Bodine PV et al., Bone, 2009

Follow-up work characterised dual modulation of canonical Wnt — anabolic on osteoblasts, attenuating osteoclastogenesis (Liu et al., J Bone Miner Res, 2021) — and separate research groups have shown the same SFRP1 lift can reactivate quiescent adult neural progenitors (Donega et al., Nat Commun, 2022). For topical scalp protocols at 0.5–1% these systemic effects are not the point, but they confirm the mechanism is real and reproducible across Wnt-driven tissues.

Why the Topical Route Matters#

Wnt is a fundamental developmental pathway, and chronic systemic over-activation is associated with colorectal, hepatocellular, and other Wnt-driven malignancies in the broader oncology literature. Keeping WAY-316606 topical — at concentrations that achieve local dermal-papilla exposure without meaningful systemic absorption — is the community's hedge against that concern. Combined with the ligand-limited mechanism, this is the rationale for restricting protocols to topical 0.25–1.5% formulations rather than the oral mg/kg dosing used in the rodent bone work, and it is why a history of any Wnt-driven malignancy or familial adenomatous polyposis is a hard contraindication regardless of route.

Common (most users)#

Most adverse effects reported in DIY topical practice trace to the vehicle, not the molecule. WAY-316606 itself has no documented systemic toxicity in topical use, and no human safety data exist either way.

• Scalp itching / stinging on application — driven by the DMSO + ethanol carrier. Drop DMSO to 15–20% of vehicle volume, bump propylene glycol, and add 5–10% water to take the edge off.
• Transient redness or warmth at application sites — usually settles within 30 minutes. If it persists, the formulation is too aggressive; dilute the vehicle or switch to a lower-ethanol cosmetic base.
• Dry, flaky scalp — common with high-ethanol vehicles. A weekly emollient (jojoba, squalane) on non-application days handles this without interfering with absorption.
• Sulfur / chemical smell — DMSO breath and body odor is a known cosmetic side effect of any DMSO-vehicle topical (RU58841 users see the same thing). Application at night, hair washed in the morning, minimises social impact.
• Shedding in the first 4–8 weeks — anagen synchronisation shed, the same pattern minoxidil produces. The protocol is held, not abandoned; the shed resolves into new growth.

Uncommon (dose-dependent or individual)#

• Contact dermatitis — more likely at 1–1.5% formulations or with daily DMSO exposure on broken skin. Back off to 0.5%, switch to every-other-day for two weeks, then retitrate.
• Scalp folliculitis — usually a hygiene / vehicle interaction rather than the active compound. Rotate to a fresh batch, ensure the application bottle isn't contaminated, and consider a ketoconazole 2% wash twice weekly.
• Mild irritation at the hairline / forehead from product migration — apply more conservatively, allow full drying before lying down.
• No bloodwork is mandated for WAY-316606 specifically, since it is topical and non-endocrine. Users running it inside a larger AAS or finasteride stack monitor the labs relevant to those compounds (LH, FSH, total/free T, E2, lipids), not WAY-316606.

Rare but serious#

These are theoretical or extrapolated risks — none have been documented in topical use, but they sit in the mechanism and deserve naming.

• Systemic chronic Wnt over-activation is mechanistically implicated in colorectal and hepatocellular carcinoma in the broader oncology literature. Hawkshaw and colleagues argue the "ligand-limited" design of SFRP1 antagonism mitigates this, since WAY-316606 cannot drive Wnt signalling where no endogenous ligand is present:

  "WAY-316606, a specific SFRP1 antagonist, significantly enhanced human hair shaft elongation and hair keratin expression in cultured human scalp hair follicles." — Hawkshaw et al. 2018, PLoS Biol

  The ex vivo data are clean; the long-term human dataset does not exist. Keeping the route topical is the conservative posture until one does.

• New or changing pigmented scalp lesions — any mole or pigmented lesion in the application field that changes size, colour, or border during use should trigger dermatology review and discontinuation. Wnt is implicated in melanocyte biology, and although nothing has been reported in topical practice, this is the right warning sign to act on.

• Severe vehicle reaction (DMSO hypersensitivity) — rare, but DMSO can produce systemic reactions in sensitive individuals (hives, swelling, anaphylactoid response). Stop immediately if hives or facial swelling appear.

Hard contraindications#

These are not soft cautions. They are the lines that do not get crossed.

• Personal or strong family history of any Wnt-driven malignancy — colorectal cancer, hepatocellular carcinoma, certain medulloblastomas, desmoid tumours. WAY-316606 directly amplifies the pathway implicated. Do not use.

• Familial adenomatous polyposis (FAP) or known APC-pathway mutations — same reasoning, with a much higher baseline risk. Hard no.

• Pregnancy and lactation — Wnt signalling is fundamental to embryogenesis and early development. No data, no use:

  "WAY-316606 attenuated osteoclastogenesis and promoted bone formation via dual modulation of canonical Wnt signaling, suggesting downstream effects beyond the hair follicle." — Liu et al. 2021, J Bone Miner Res

  Whatever the systemic absorption from a topical actually is, this is not the compound to gamble pregnancy on.

• Active scalp psoriasis or seborrheic dermatitis flare — keratinocyte proliferation under Wnt activation is a poor combination with a hyperproliferative scalp disorder. Resolve the dermatosis first.

• Co-application with other Wnt activators — topical valproic acid, lithium, GSK-3β inhibitors. Stacking two arms of the same pathway is uncharacterised and is not recommended.

• Oral or systemic administration — no oral or injectable protocol has any community or clinical support. The mechanism is what makes the topical route the only defensible one.

Gender, AAS-cycle, and PCT considerations#

WAY-316606 has no endocrine activity. It does not bind androgen receptors, does not inhibit 5-alpha-reductase, does not aromatise, and does not perturb the HPTA. This is the core reason the compound exists in the looksmaxxing toolkit at all — it offers a pro-anagen mechanism that does not cost libido, erectile function, or semen parameters the way oral finasteride or dutasteride can. No PCT is relevant, and no PCT interaction exists when WAY-316606 is layered onto an AAS cycle alongside topical AR antagonists (RU58841, pyrilutamide, clascoterone). Female users running it for diffuse thinning face no virilization or hormonal concern; the only female-specific contraindications are pregnancy and lactation, listed above. The compound is dosed identically across the subject pool because the mechanism is non-hormonal.